Oka Varicella Vaccine, also known as VARIVAX, is a live, attenuated viral vaccine used for the prevention of chickenpox, a highly contagious disease caused by the varicella-zoster virus (VZV). This vaccine is made from a weakened form of the virus that causes chickenpox, providing immunity against the disease.
The name "Oka" refers to the strain of the varicella-zoster virus used in the vaccine, which was originally isolated from a child in Japan. The strain was attenuated, or weakened, through extensive laboratory procedures, rendering it unable to cause illness in healthy individuals.
The Oka Varicella Vaccine is administered via an injection, typically given to children between 12 and 15 months of age, followed by a booster dose between the ages of 4 and 6. The vaccine can also be given to older children, adolescents, and adults who have not previously been immunized.
Upon receiving the vaccine, the body's immune system recognizes the weakened virus and mounts a defense, producing antibodies that provide long-term protection against the varicella-zoster virus. This helps prevent the development of chickenpox or reduce its severity if infection occurs.
Common side effects of the Oka Varicella Vaccine may include soreness or redness at the injection site, mild fever, or a rash. Serious adverse effects are extremely rare.
Overall, the Oka Varicella Vaccine has proven to be highly effective in preventing chickenpox, reducing the incidence of this viral illness and its associated complications.
